|
|
 |
|
|
|    | |
|
|
|
|
|
Research and Development25 May 2006 Placenta praevia risk increased after IVFResearch published online in Human Reproduction suggests that the risk of placneta praevia rose from about three in 1,000 pregnancies in the general population, to 16 in 1,000 for women who had had IVF.
25 May 2006 Prostate therapy benefits doubtedResearch published in the British Journal of Cancer suggests that many men diagnosed with low-grade prostate cancer do not benefit from radical treatment. The researchers calculated that, even without treatment, only about 1% of men aged 55-59 with diagnosed low-grade disease would die within 15 years. Side effects of radical treatment such as surgery and radiotherapy can include incontinence and impotence. The Department of Health said its advisers would consider the findings.
4 May 2006 First clinical trial for women with hereditary breast cancer launchedBreakthrough Breast Cancer and Cancer Research UK have launched the world’s first international clinical trial to treat women with a form of hereditary breast cancer that has come back. Women who have been diagnosed with a faulty BRCA1 or 2 gene and whose breast cancer has returned elsewhere in the body will be eligible. The BRCA Tial will compare carboplatin, a platinum-based drug not normally used to treat breast cancer, with standard chemotherapy treatment.
4 May 2006 Sentinel Node Biopsy shortens recovery timeResearch published in Journal of the National Cancer Institute suggests that sentinel node biopsy reduced recovery times by three days compared to standard treatment. Those women who had the new style of biopsy saw a 70% reduction in arm swelling and a 60% reduction in pain . The Department of Health has funded Professor Mansel to roll out training in the technique across the country after successful initial trials.
3 May 2006 Drug to reduce tissue damage after a heart attackResearch published in the journal Nature reports that scientists are designing a drug they hope will reduce tissue damage after a heart attack. It works by blocking the destructive effect of a compound called C-reactive protein (CRP). The researchers have developed a potent compound called bis(phosphocholine)-hexane. It was found to inhibit CRP in the test tube, and to block its damaging effects in experiments to simulate the effect of a heart attack.
28 April 2006 Hormonal male contraceptive regimens show full reversibilityResearch published in The Lancet suggests that male hormonal contraception can be reversed within a few months. Researchers looked at data on more than 1,500 men around the world who had taken part in tests of some form of hormonal contraception. On average, men took three to four months to recover full fertility.
Archives: View all items in this category. |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
